Clinical Trial: Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210047) titled 'Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients' on Sept. 19.

Brief Summary: The goal of this clinical trial is to learn if the antibody drug HuL001, combined with

Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients. It will also learn about the safety and tolerability of the therapeutic combination. The objectives of this study are:

1. To evaluate the safety and tolerability of HuL001 (in combination with Len/Dex).

2. To evaluate the efficacy of HuL001 (in combination with Len/Dex).

Researchers will use the antibody drug HuL001, combined with Len/Dex, to see if this works for Multiple Myeloma the...